Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05819255 · ClinicalTrials.gov registry record
TRAQinform Assessment of Immunotherapy Response
A clinical trial, sponsored by AIQ Solutions.
- Completed
- Registry status
- 26
- Enrollment target
NCT05819255: Completed study, sponsored by AIQ Solutions.
NCT05819255 is a clinical trial that has completed, run by AIQ Solutions. The registered enrollment target is 26 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05819255 has completed, sponsored by AIQ Solutions.
- COMPLETED
- Registry status
- 26 participants
- Enrollment target
Study Summary
The intent of this study is to evaluate the actionable information output from the TRAQinform Immuno technology in a prospective, non-interventional clinical study. Subjects with metastatic melanoma treated with standard of care (SOC) dual-agent immunotherapy will be enrolled. Subjects will receive SOC immunotherapy monitored for treatment response with FDG PET/CT's at baseline (SOC), after 3-4 weeks of treatment (non-SOC) and 12 at weeks of treatment (SOC).
Interventions
- OTHER Non-Interventional
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2023-06-23 |
| Est. Completion | 2025-04-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05819255
The ClinicalTrials.gov registry entry for NCT05819255 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AIQ Solutions, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Non-Interventional is the first listed.
NCT05819255 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05819255 about?
NCT05819255 is a clinical study titled "TRAQinform Assessment of Immunotherapy Response". The intent of this study is to evaluate the actionable information output from the TRAQinform Immuno technology in a prospective, non-interventional clinical study. Subjects with metastatic melanoma treated with standard of care (SOC) dual-agent immunotherapy will be enrolled. Subjects will receive ...
What is the current status of trial NCT05819255?
This trial is currently completed. The enrollment target is 26 participants. The study started on 2023-06-23. Estimated completion is 2025-04-30.
What interventions are being tested in trial NCT05819255?
The interventions under investigation include: Non-Interventional (OTHER).
Who is sponsoring clinical trial NCT05819255?
This trial is sponsored by AIQ Solutions, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.